AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DIMERIX LTD

0.280

+0.0051.82%

Volume:1.37M

Turnover:372.04K

Market Cap:168.11M

PE:-5.63

High:0.280

Open:0.280

Low:0.260

Close:0.275

52wk High:0.665

52wk Low:0.157

Shares:600.40M

Float Shares:467.70M

Volume Ratio:1.57

T/O Rate:0.29%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.050

EPS(LYR):-0.024

ROE:-594.54%

ROA:-28.84%

PB:-11.39

PE(LYR):-11.84

Loading ...

Overview Company News Filings

Concept

Novel Coronavirus Treatment+0.48%

Pharmaceutical Companies-0.94%

Capital Flow

Inflow:

Outflow:

News

Dimerix Posts Loss for Year Attributable of A$29.8 Million

Dimerix Ltd - Loss for the Year Attributable A$29.8 Mln

THOMSON REUTERS

Dimerix Receives Initial $10 Million Upfront Payment Under Everest Medicines License Deal; Shares Gain 4%

MT Newswires Live

Dimerix Completes Transfer of Acute Kidney Injury Drug Candidate's US Investigational New Drug Application, Shares Up 6%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/DXB.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DXB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","market":"AU","secType":"STK","nameCN":"DIMERIX LTD","latestPrice":0.28,"timestamp":1788156720000,"preClose":0.275,"halted":0,"volume":1368829,"delay":0,"changeRate":0.018181818181818195,"nameEN":"DIMERIX LTD","floatShares":467696880,"shares":600396776,"eps":-0.0497,"marketStatus":"Closed","change":0.005,"latestTime":"08-31 16:12:00 AEST","open":0.28,"high":0.28,"low":0.26,"amount":372035,"amplitude":0.072727,"askPrice":0.28,"askSize":10116,"bidPrice":0.27,"bidSize":199127,"shortable":3,"etf":0,"ttmEps":-0.0497,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.275,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":1.570342,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"DXB.AU","preClose":0.275,"auctionPrice":0.28,"auctionVolume":144774,"auctionTime":1788156603182,"referencePrice":0.28,"referenceTime":1788172203092,"auction":3,"marketStatus":"盘后竞价","timestamp":1788156603182}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","floatShares":467696880,"roa":"-28.84%","roe":"-594.54%","lyrEps":-0.023645,"volumeRatio":1.570342,"shares":600396776,"dividePrice":0,"high":0.28,"amplitude":0.072727,"preClose":0.275,"low":0.26,"week52Low":0.157,"pbRate":"-11.39","psRate":"24.09","week52High":0.665,"institutionHeld":0,"latestPrice":0.28,"committee":0.903309,"eps":-0.0497,"divideRate":0,"volume":1368829,"delay":0,"ttmEps":-0.0497,"open":0.28,"prevYearClose":0.55,"prevWeekClose":0.275,"prevMonthClose":0.245,"prevQuarterClose":0.205,"fiveDayClose":0.31,"twentyDayClose":0.26,"sixtyDayClose":0.175,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DXB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DXB.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662721510","title":"Dimerix Posts Loss for Year Attributable of A$29.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662721510","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662721510?lang=en_us&edition=fundamental","pubTime":"2026-08-27 09:49","pubTimestamp":1787795375,"startTime":"0","endTime":"0","summary":"Aug 27 (Reuters) - Dimerix Ltd::*LOSS FOR THE YEAR ATTRIBUTABLE A$29.8 MILLION*REVENUES FROM ORDINARY ACTIVITIES FOR THE YEAR A$7 MILLION*Further company coverage: DXB.AX* ((Reuters.Briefs@thomsonreut","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nRSD9nJQBR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","BK7508","DXB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662282967","title":"Dimerix Ltd - Loss for the Year Attributable A$29.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662282967","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662282967?lang=en_us&edition=fundamental","pubTime":"2026-08-27 06:58","pubTimestamp":1787785108,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N17L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DXB.AU","BK7067","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660340889","title":"Dimerix Receives Initial $10 Million Upfront Payment Under Everest Medicines License Deal; Shares Gain 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660340889","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660340889?lang=en_us&edition=fundamental","pubTime":"2026-08-20 11:53","pubTimestamp":1787197984,"startTime":"0","endTime":"0","summary":"Dimerix  received an initial $10 million upfront payment under a license agreement with Everest Medicines, according to a Thursday filing with the Australian bourse.Everest holds exclusive rights to commercialize DMX-200 for the treatment of kidney disease focal segmental glomerulosclerosis across Greater China, South Korea, and Southeast Asia.Dimerix said it is eligible to receive up to an additional $330 million in success-based development, regulatory, and commercial milestone payments, in addition to tiered royalties on net sales of the DMX-200 in the licensed regions.The company's shares gained 4% in recent Thursday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","BK7508","BK7067","BK7501","DXB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660243106","title":"Dimerix Completes Transfer of Acute Kidney Injury Drug Candidate's US Investigational New Drug Application, Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660243106","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660243106?lang=en_us&edition=fundamental","pubTime":"2026-08-17 09:43","pubTimestamp":1786930994,"startTime":"0","endTime":"0","summary":"Dimerix  said it completed the transfer of the investigational new drug application in the US for its acute kidney injury drug candidate, DMX-652, from Mission Therapeutics, according to a Monday Australian bourse filing.Dimerix plans to advance DMX-652 into a phase 2 clinical trial for acute kidney injury associated with cardiac surgery during the second half, to investigate its potential to prevent kidney injury and preserve renal function.Its shares jumped 6% in recent trading on Monday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7501","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":11,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/DXB.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Novel Coronavirus Treatment","id":"package_au_concept_xgzlg","bkCode":"BK7501","changeRate":0.004807},{"market":"AU","name":"Pharmaceutical Companies","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":-0.009387}]}}